Neuroimaging for Migraine

Age: 18 - 65

Sex: Female

Trial Phase: Academic

Sponsor: Mayo Clinic

Disqualifiers: Cancer, Organ transplant, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

50 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this research is to better understand brain white matter hyperintensities (WMH) in women with migraines

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team for clarification.

What data supports the effectiveness of the treatment Brain Neuroimaging for migraines?

The research suggests that neuroimaging is useful in identifying significant brain abnormalities and ruling out other causes of headaches, but it does not provide direct evidence of its effectiveness as a treatment for migraines. ^{1 2 3 4 5}

Is neuroimaging safe for humans?

The research articles focus on how neuroimaging helps us understand migraines better, but they do not provide specific information about the safety of neuroimaging itself. Generally, neuroimaging techniques like MRI and PET are considered safe for humans, as they are commonly used in medical settings. ^{6 7 8 9 10}

How does neuroimaging treatment for migraine differ from other treatments?

Neuroimaging treatment for migraine is unique because it uses advanced brain imaging techniques to understand and potentially target the brain's role in migraines, rather than focusing on vascular causes like traditional treatments. This approach aims to explore the brain's structure and function to better understand migraine pain and develop more effective interventions. ^{11 12 13 14 15}

Research Team

Catherine Chong, PhD

Principal Investigator

Mayo Clinic

Eligibility Criteria

This study is specifically for women aged 20-45 who have white matter hyperintensities (WMH) on their brain MRI, which can be related to conditions like migraines or small vessel disease.

Inclusion Criteria

I am female.

I am between 20 and 45 years old.

Presence of WMH on MRI.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging Assessment

Participants undergo brain neuroimaging to assess white matter hyperintensities

3 months

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after imaging assessment

4 weeks

Treatment Details

Interventions

• Brain Neuroimaging

Trial Overview The trial is focused on using brain neuroimaging techniques to investigate the presence and characteristics of WMH in women suffering from migraines.

Participant Groups

Group I: Small vessel ischemic (SVI) disease cohort Experimental Treatment 1 Intervention

Women diagnosed with SVI disease and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.

Group II: Multiple sclerosis (MS) cohort Experimental Treatment 1 Intervention

Women diagnosed with MS and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.

Group III: Migraine cohort Experimental Treatment 1 Intervention

Women with migraine and presence of white matter hyperintensities (WMH) on clinical magnetic resonance imaging (MRI) will have brain neuroimaging.

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials

3,427

Recruited

3,221,000+

References

1. Korea (South) pubmed.ncbi.nlm.nih.gov

Diagnostic Neuroimaging in Headache Patients: A Systematic Review and Meta-Analysis. [2020]

2. United Arab Emirates pubmed.ncbi.nlm.nih.gov

Functional Neuroimaging Biomarkers in Migraine: Diagnostic, Prognostic and Therapeutic Implications. [2020]

3. United States pubmed.ncbi.nlm.nih.gov

Narrative review of neuroimaging in migraine with aura. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Value of Patient-Directed Brain Magnetic Resonance Imaging Scan with a Diagnosis of Migraine. [2019]

6. Netherlands pubmed.ncbi.nlm.nih.gov

Targeting migraine treatment with neuroimaging-Pharmacological neuroimaging in headaches. [2021]

7. England pubmed.ncbi.nlm.nih.gov

Evaluation and proposal for optimization of neurophysiological tests in migraine: part 2--neuroimaging and the nitroglycerin test. [2019]

8. England pubmed.ncbi.nlm.nih.gov

New insights into migraine: application of functional and structural imaging. [2013]

9. England pubmed.ncbi.nlm.nih.gov

Migraine changes the brain: neuroimaging makes its mark. [2022]

10. United States pubmed.ncbi.nlm.nih.gov

Neuroimaging of migraine. [2021]

11. Poland pubmed.ncbi.nlm.nih.gov

Altered functional brain imaging in migraine patients: BOLD preliminary study in migraine with and without aura. [2019]

12. France pubmed.ncbi.nlm.nih.gov

[Neuro-imaging studies in migraine]. [2016]

13. Italy pubmed.ncbi.nlm.nih.gov

From neuroimaging to clinical setting: what have we learned from migraine pain? [2022]

14. United States pubmed.ncbi.nlm.nih.gov

Functional neuroimaging of primary headache disorders. [2019]

15. United States pubmed.ncbi.nlm.nih.gov

Functional neuroimaging of primary headache disorders. [2019]